StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $28.50 | $28.17 | -1.16% | 0.6M |
| 05-18 | $28.16 | $28.21 | +0.18% | 0.8M |
| 05-19 | $28.46 | $27.73 | -2.57% | 0.6M |
| 05-20 | $27.78 | $28.50 | +2.59% | 0.7M |
| 05-21 | $28.06 | $28.50 | +1.57% | 0.2M |
No sell-side coverage available for AGIO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $20.75M | $54.03M | $34.06M | $21.18M |
Operating Income | $-110.03M | $-472.13M | $-350.55M | $-233.69M |
Net Income | $-99.11M | $-412.78M | $-304.74M | $-112.02M |
EPS (Diluted) | $-1.69 | $-7.12 | $-5.27 | $-3.49 |
Total Assets | $1.18B | $1.30B | $1.39B | $1.47B |
Total Liabilities | $75.88M | $104.11M | $101.38M | $101.68M |
Cash & Equivalents | $113.60M | $89.13M | $92.71M | $80.87M |
Free Cash Flow OCF − CapEx | $-119.69M | $-377.29M | $-279.96M | $-190.25M |
Shares Outstanding | 59.34M | 58.45M | 58.28M | 58.04M |
AGIO is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.